Manufactures active pharmaceutical ingredients (APIs), also known as bulk drugs, which are the chemical compounds used by other drug makers to produce finished medicines. The product slate is expanding into regulated-market molecules, with new additions cited as Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate. Revenue comes from two streams: domestic sales (around 54% of revenue) and exports (around 46%), with Africa (33% of exports), Asia (35%), and Europe (24%) as the named export geographies. The manufacturing base produced 1,733 metric tonnes in FY26 (up about 25% year-on-year), running against installed capacity of 2,400 MTPA, and the facilities cleared USFDA and EU GMP inspections with zero 483 observations. Costs are dominated by raw materials at 66.1% of revenue, with employee cost at 3.4% and other operating expenses at 10.9%. Depreciation is 1.5% and capex 1.0% of revenue, indicating a relatively capital-light profile. EBITDA margin compressed to 8.56% in FY26, with net profit of Rs. 41.05 crore on revenue of Rs. 771.66 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Domestic API sales (54%), Export API sales (46%). API manufacturer with export exposure to regulated and semi-regulated markets; capital-light with low capex at 1.0% of revenue.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 487 | 527 | 647 | 662 | 772 |
| EBITDA (ex other income) | 47 | 51 | 75 | 61 | 62 |
| margin % | 9.6 | 9.7 | 11.6 | 9.2 | 8.0 |
| Owners' profit | 31 | 36 | 60 | 47 | 41 |
| EPS, as reported (₹) | 6.10 | 7.22 | 11.98 | 9.45 | 4.10 |
| ROE % · ROCE % | 14.3 · 18.5 | 15.0 · 19.6 | 20.6 · 26.8 | 14.5 · 18.8 | 11.7 · 15.4 |
| Debt / equity (x) | 0.01 | 0.00 | 0.01 | 0.03 | 0.00 |
| Cash from operations | 29 | 54 | 13 | 37 | (3) |
| Capex | (2) | (2) | (5) | (20) | (8) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 160 | 198 | 186 | 372 | 197 | 202 | 194 |
| Profit before tax | 18 | 13 | 17 | 11 | 21 | 18 | 16 | 17 |
| Net profit | 15 | 10 | 12 | 8 | 16 | 13 | 12 | 11 |
| EPS (₹) | 3.00 | 2.06 | 2.49 | 1.66 | 1.59 | 1.34 | 1.17 | 1.14 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 19 Aug 2026 · Q1 FY27: profit up 38%, EBITDA margin expands to 9.99% | investor communications | medium | — | — |
| 14 Aug 2026 · Anuh Pharma AGM 2026: Rs 1.50 dividend, all 9 resolutions passed | board shareholder meetings | low | — | — |
| 12 Aug 2026 · Anuh Pharma reports proceedings of its 66th AGM | board shareholder meetings | medium | — | — |
| 9 Aug 2026 · Anuh Pharma publishes Q1 FY27 unaudited results in newspapers | compliance | minimal | — | — |
| 7 Aug 2026 · Board approves Q1 results, revised RPT policy; promoter reclassification withdrawn | results | medium | — | — |
| 7 Aug 2026 · Three promoter group members withdraw reclassification to public category | ownership changes | medium | — | — |
| 7 Aug 2026 · ANUH PHARMA Q1 FY27 PAT up 38% at Rs 11.4 cr, EBITDA margin expands to 10% | results | medium | — | — |
| 7 Aug 2026 · Q1 FY27 results: PAT up 38%, EBITDA margin expands to 10% | results | high | — | — |
| 3 Aug 2026 · Board meeting on 07 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 18 Jul 2026 · Anuh Pharma sends AGM notice by post to shareholders without registered email | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 18.1 | 28.9 | 52 of 169 | 70% |
| P/B | 2.7 | 3.3 | 70 of 163 | 57% |
| ROCE | 15.3 | 10.8 | 61 of 183 | 67% |
| ROE | 11.7 | 10.4 | 74 of 171 | 57% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 10.0 | 17.5 | 121 of 165 | 27% |
| Revenue growth | 3.9 | 16.3 | 116 of 161 | 28% |
| Profit growth | 37.6 | 30.9 | 75 of 158 | 53% |
| Market cap | 952 | 839 | 90 of 182 | 51% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
